Virtual reality to ease ongoing breathlessness in people with ALS on breathing support
Tests immersive virtual reality for ongoing breathlessness in adults with ALS using breathing support.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- Paris, FranceSee the site
- Trial code
- Registry title
- Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality
- Status
- Recruiting
- People taking part
- 35 people, planned
- Started
- 4 Apr 2024
- Expected to end
- 4 Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Immersive virtual reality (IVR) & Music therapy
- Record updated
- 25 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with ALS who still feel short of breath although they use non-invasive ventilation (NIV).
- Age
- 18 years or older
- Sex
- Women and men can join
- Disease stage
- ALS confirmed by the revised El Escorial criteria. Breathing failure from a weak diaphragm. Shortness of breath at rest scored 3 or more on a 0 to 10 scale, in a semi-sitting position. Stable condition, with no hospital stay for acute heart, breathing or nerve failure in the last 4 weeks.
- Earlier treatment
- Must have used non-invasive ventilation for more than a month. Care is given in an ambulatory setting (day care hospital).
Main reasons for not taking part
- Brain or nerve disorders such as dementia, brain tumor, stroke or Parkinson's disease
- Diagnosed psychiatric illness, or taking antipsychotic treatment
- Fear of heights, closed spaces or light (acrophobia, claustrophobia, photophobia)
- Hearing loss or visual impairment
- Under guardianship or curatorship
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- ≥ 18 years old
- Diagnosis of ALS confirmed according to the revised criteria of El Escorial
- Respiratory failure due to diaphragmatic dysfunction treated by non-invasive ventilation for more than a month
- Care provided in an ambulatory setting (day care hospital)
- Persistent dyspnea at rest ≥ 3 across a numerical scale (0 to 10) in a semi-sitting position
- Stable clinical condition, i.e., no episode of acute cardiac, respiratory and/or neurological failure leading to hospitalization in the previous 4 weeks
- Free, prior and informed written consent about the study has been obtained
- Benefiting a social security (French health insurance system)
Who cannot take part
- Diagnosed psychiatric illness (severe depression, psychosis) or receiving antipsychotic treatment
- Neurological disorders according to a neurological evaluation dating from less than one year, in particular diagnosed dementia (frontotemporal dementia, Alzheimer's disease, etc.), brain pathology (tumor, stroke, Parkinson's disease, etc.)
- Visual impairment
- Acrophobia
- Claustrophobia
- Photophobia
- Hearing loss
- Subject under guardianship or curatorship
Where in France
- Service de PneumologieParis, FranceContact: Capucine MORELOT PANZINITaking people
About the trial
What the trial wants to find out
The evolution of amyotrophic lateral sclerosis (ALS) is marked by dyspnea, anxiety and pain, major determinants of suffering induced by this disease. The only palliative treatment for respiratory failure is non-invasive ventilation (NIV), which compensates failing respiratory muscles and relieves dyspnea, improves quality of life and increases life expectancy. In ALS patients, the persistence of dyspnea outside of NIV sessions has highlighted the need for therapeutic alternatives in the treatment of persistent dyspnea, including immersive virtual reality (IVR) and auditory distraction through music (music therapy). This study evaluates the effect of IVR on respiratory discomfort in ALS patients with persistent dyspnea treated with NIV.
The 2 groups in the trial
- Patients starting with RVIExisting treatment, for comparison
Patients will begin by wear a virtual reality headset (GAMIDA®) and headphones (Bose®). A tablet (Samsung®) equipped with "Healthy Mind" software will allow patients to live a 360° visual and auditory 3D experience via Bluetooth connection. After that patients will be handed a smartphone with the Spotify® application to listen to music. Patients will wear headphones.
Treatment: Immersive virtual reality (IVR) & Music therapy
- Patients starting with music therapyExisting treatment, for comparison
Patients will begin by handed a smartphone with the Spotify® application to listen to music. Patients will wear headphones. After that patients will wear a virtual reality headset (GAMIDA®) and headphones (Bose®). A tablet (Samsung®) equipped with "Healthy Mind" software will allow patients to live a 360° visual and auditory 3D experience via Bluetooth connection.
Treatment: Immersive virtual reality (IVR) & Music therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality
- Plain-language title
- Virtual reality to ease ongoing breathlessness in people with ALS on breathing supportGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 February 2026